Novavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 4,600 Shares

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 4,600 shares of the business’s stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the completion of the sale, the director now directly owns 57,160 shares in the company, valued at $484,716.80. This represents a 7.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Novavax Price Performance

Novavax stock opened at $8.85 on Friday. The firm has a market capitalization of $1.42 billion, a PE ratio of -3.92 and a beta of 2.07. The company’s 50-day moving average is $8.69 and its 200-day moving average is $11.34. Novavax, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $23.86.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.07. The firm had revenue of $84.51 million for the quarter, compared to analyst estimates of $65.80 million. The firm’s revenue for the quarter was down 54.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.26) earnings per share. As a group, analysts expect that Novavax, Inc. will post -1.44 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Amalgamated Bank grew its stake in Novavax by 26.9% in the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,036 shares during the last quarter. Ensign Peak Advisors Inc grew its stake in Novavax by 3.0% in the 2nd quarter. Ensign Peak Advisors Inc now owns 44,900 shares of the biopharmaceutical company’s stock valued at $568,000 after buying an additional 1,300 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,598 shares during the last quarter. Victory Capital Management Inc. grew its stake in Novavax by 12.0% in the 3rd quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 2,072 shares during the last quarter. Finally, Banque Cantonale Vaudoise grew its stake in Novavax by 500.0% in the 2nd quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 2,500 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on NVAX shares. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of Novavax in a research report on Tuesday, December 10th. B. Riley reissued a “buy” rating and set a $26.00 price target (up from $23.00) on shares of Novavax in a research report on Thursday, October 10th. Finally, Jefferies Financial Group cut their price target on shares of Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $17.83.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.